TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Preventing Violence Among Veterans in Substance Use Disorder Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with severe and recent violence (i.e., injuring another person in the past year) will be eligible for the RCT.~* Eligible patients also will meet DSM-IV criteria for either alcohol or illicit drug (e.g., cocaine, marijuana, opiates, etc.) abuse/dependence.~* The study will include those with comorbid mood and/or anxiety problems (e.g., depression, PTSD and other anxiety disorders), whether or not on medication at the point of recruitment, with the exception of those who have schizophrenia and/or are mentally incompetent (e.g., unable to provide informed consent).~* A brief mental status screen will with an established cutoff will be required for competency.~Exclusion Criteria:~* Participants who are suicidal (ideation, intent and plan) at the point of recruitment will not be enrolled in the study. Rather, research staff will inform clinical staff at the study site if a potential participant is currently suicidal.~* Participants who report transient suicidal ideation but no intent or plan will be eligible to participate.~* As noted, individuals with schizophrenia and/or who are mentally incompetent to consent for participation will be excluded. Finally, participants who live outside the study catchment area (i.e., a 45 mile radius of the VA Ann Arbor Healthcare System) will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: MI-CBT (Type: EXPERIMENTAL): MI-CBT (six sessions during acute treatment phase integrating motivational interviewing and cognitive behavioral approaches)
- Arm 2: MI-CBT+CC (Type: EXPERIMENTAL): MI-CBT+CC (acute phase MI-CBT intervention plus a subsequent 12-week phone based continuing care counseling intervention)
- Arm 3: E-TAU (Type: ACTIVE_COMPARATOR): E-TAU (enhanced treatment as usual - includes brief session and provision of resources)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SEGUDIAB Study: Evaluation of Safety in the Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of diabetes~* Aged between 45 and 75 years~Exclusion Criteria:~* No data in informatic system~* Severe illness~* Controlled only by specialists

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Usual clinical health care
- Intervention (Type: EXPERIMENTAL): Behavioural program of education for health professionals. Standardized program of 6 hours for health professionals ( doctors and nurses )

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female at least 9 years of age and older;~2. Written and verbal informed consent must be obtained. Subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches age of consent during the study they should be re-consented at the next study visit);~3. Subject must have a score of 3 (moderate) or 4 (severe) on the Evaluator's Global Severity assessment at the baseline visit;~4. Subjects with facial acne inflammatory lesion (papules, pustules, and nodules) count no less than 20 but no more than 50;~5. Subjects with facial acne non-inflammatory lesion (open and closed comedones) count no less than 25 but no more than 100;~6. Subjects with two or fewer nodules~Exclusion Criteria:~1. Use of an investigational drug or device within 30 days of enrollment or participation in a research study concurrent with this study;~2. Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gram-negative folliculitis, dermatitis, eczema;~3. Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive;~4. Subjects with a facial beard or mustache that could interfere with the study assessments;~5. Subjects with more than two (2) facial nodules;~6. Evidence or history of cosmetic-related acne

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- IDP-123 Lotion (Type: EXPERIMENTAL): Tazarotene 0.045% Lotion
- IDP-123 Vehicle Lotion (Type: PLACEBO_COMPARATOR): Vehicle Lotion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exercise in Obese Diabetic Patients With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diabetes mellitus~* CKD Stages 2-4~* BMI \> 30~* Persistent proteinuria (urine protein/creatinine \> 200 mg/g for \> 3 mo)~* On treatment with ACE inhibitor or ARB~* On treatment with aspirin~* On treatment with statin (if LDL \> 100)~Exclusion Criteria:~* Symptomatic neuropathy/retinopathy~* Positive stress test due to coronary arterial disease~* Symptomatic cardiovascular disease~* Congestive heart failure (New York Heart Association Class III or IV)~* Chronic obstructive pulmonary disease (FEV1 \< 50% predicted and/or requires supplemental oxygen support during exercise)~* Complaints of angina during the stress test~* Cerebrovascular disease/cognitive impairment~* Renal transplant~* Inability to walk on the treadmill~* Any unforeseen illness or disability that would preclude exercise testing or training~* Participation in a formal exercise program within the previous 12 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Control group
- Exercise (Type: EXPERIMENTAL): Exercise Group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Evaluation of 3K3A-APC in Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Acute ischemic stroke~* Able to receive IV tPA, mechanical thrombectomy or both~* National Institutes of Health Stroke Scale (NIHSS) score of ≥ 5~* Signed informed consent~* Mechanical thrombectomy subjects only: onset time to arterial puncture time \< 6 hours~Exclusion Criteria:~* History of stroke or penetrating head injury within 90 days prior to enrollment~* History of previous or current diagnosis of intracranial hemorrhage that represents a potential for re-hemorrhage if subjected to thrombolytic therapy or mechanical thrombectomy~* Moyamoya disease, cerebral arterio-venous malformation (AVM), known unsecured aneurysm requiring intervention during the acute study period~* Presence of other neurological or non-neurological co-morbidities that may lead, independently of the current stroke, to further deterioration in the subject's neurological status during the trial period~* Presence of premorbid neurological deficits and functional limitations assessed by a retrospective Modified Rankin Scale (mRS) score of ≥ 2~* Mechanical thrombectomy subjects only: baseline non-contrast CT scan revealing a large core occlusion as defined by local protocol~* Prolonged prothrombin time (PT) or activated partial thromboplastin time (aPTT)~* Severe hypertension or hypotension~* Glomerular filtration rate (GFR) \<35 mL/min~* Blood glucose concentration \< 50 mg/dL~* Prior exposure to any exogenous form of APC

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 120 µg/kg of 3K3A-APC (Type: ACTIVE_COMPARATOR): 3K3A-APC, q12h for up to 5 doses
- 240 µg/kg of 3K3A-APC (Type: ACTIVE_COMPARATOR): 3K3A-APC, q12h for up to 5 doses
- 360 µg/kg of 3K3A-APC (Type: ACTIVE_COMPARATOR): 3K3A-APC, q12h for up to 5 doses
- 540 µg/kg of 3K3A-APC (Type: ACTIVE_COMPARATOR): 3K3A-APC, q12h for up to 5 doses
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo, q12h for up to 5 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy for Lung Cancer in HIV-positive Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* NSCLC histologically (highly recommended) and/or cytologically confirmed, stage III (non-irradiable or inoperable) or stage IV (according to 2009 TNM classification), with other than predominantly squamous histology~* HIV seropositivity (previous or inaugural), irrespective of CD4 count or viral load~* Presence of at least one measurable lesion (RECIST v1.1)~* Subject having signed the informed consent form,~* Subject who, in the investigator's opinion, will be able to comply with the requirements and constraints of the study~* Age ≥ 18 years ≤ 75 years,~* WHO performance status: 0, 1 or 2~* Weight loss ≤ 10% of total body weight in the month before inclusion~* Estimated life expectancy ≥ 1 month,~* Covered by health insurance~Exclusion Criteria:~* Bronchial cancer already treated (other than endoscopic deobstruction)~* Cancer which is amenable to surgery or radiation (curative),~* Squamous cell lung cancer or mixed small cell and non-small cell cancer, small cell lung cancer~* Creatinine clearance (MDRD) \< 45 mL/min~* Severe hypersensitivity to any of the study products or excipients~* Severe disease or uncontrolled systemic disease (unstable or decompensated respiratory disease, cardiac, hepatic or renal disease, uncontrolled opportunistic infection)~* Significant abnormality in CBC-platelets (Hb \<9 g/dL, PNN \<1500 / mm3, platelets \< 100,000 / mm3)~* Significant abnormality in liver tests (AST, ALT \> 3x ULN, and \<5 in case of liver metastases),~* Women of childbearing age without effective contraception; pregnant or breastfeeding women~* Subject who cannot take vitamin B12, folic acid or corticosteroids~* Diffuse interstitial pneumonia~* Any geographical situation or psychological condition that precludes full understanding and compliance with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Value of Multiple Urine Flow Rate Measurements in Male Benign Prostatic Hyperplasia (BPH) Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent~* Males aged 45-85 years~* \>60% of the voiding volume is above 100 ml per voiding verified by a urinary diary~* Able to read write and understand given instructions~Exclusion Criteria:~* Patients practicing CIC~* Ongoing symptomatic UTI~* Known Neurological Disease that is affecting the bladder function~* Known past or present alcohol or drug abuse~* Involvement in the planning and conduct of the study (applies to both Astra Tech staff or staff at the study site)~* Previous enrolment or randomisation of treatment in the present study.~* Suspected poor compliance based on less than 80 % compliance to voiding diary~* Severe non-compliance to protocol as judged by the investigator and/or Astra Tech~* On alpha-blocker or 5-alpha reductase inhibitor treatment, treatment started less than 2 months prior to enrolment~* Clinic flow below 100 ml

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Disposable device first, then Digital device (Type: EXPERIMENTAL): None
- Digital device first, then Disposable device (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed, HER2-negative adenocarcinoma of the breast, with measurable or non-measurable locally recurrent or metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent.~* ECOG performance status of 0 or 1~* For women of childbearing potential, use of an acceptable and effective method of non-hormonal contraception~* For patients who have received recent radiotherapy, recovery prior to randomization from any significant acute toxicity, and radiation treatments have to be completed more than 3 weeks from randomization~Exclusion Criteria:~Disease-Specific Exclusions:~* HER2-positive status~* Prior chemotherapy for locally recurrent or metastatic disease~* Prior hormonal therapy \< 2 weeks prior to randomization~* Prior adjuvant or neo-adjuvant chemotherapy is allowed, provided its conclusion has been for at least 12 months prior to randomization~* Investigational therapy within 28 days of randomization~General Medical Exclusions:~* Life expectancy of \< 12 weeks~* Inadequate organ function~* Uncontrolled serious medical or psychiatric illness~* Active infection requiring intravenous (IV) antibiotics at screening~* Pregnancy or lactation~* History of other malignancies within 5 years prior to screening, except for tumors with a negligible risk for metastasis or death

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Paclitaxel + Bevacizumab \[Avastin\]
- B (Type: EXPERIMENTAL): Paclitaxel + Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect on Weight Loss of Exenatide Versus Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with type 2 diabetes for at least 6 months~* Have been treated with a stable dose of the following for at least 6 weeks prior to screening: \*immediate or extended release metformin, or \*a sulfonylurea, or \*a fixed-dose sulfonylurea/metformin combination therapy~* Have an HbA1c of 6.6% to 10.0%, inclusive~* Have a Body Mass Index (BMI) of 25 kg/m\^2 to 39.9 kg/m\^2, inclusive~Exclusion Criteria:~* Are treated with any of the following excluded medications: \*exogenous insulin, thiazolidinedione, or alpha-glucosidase inhibitor for more than 1 week within 6 weeks of screening; \*Symlin injection at any time; \* Byetta injection within 3 months of screening or discontinuation of therapy at any time due to adverse reaction; \*drugs that directly affect gastrointestinal motility; \*use of a weight loss drug (including those available over the counter) within 3 months of screening; \*chronic (lasting longer than 2 weeks) systemic corticosteroids (excluding topical, intranasal, and inhaled preparations) by oral, intravenous, or intramuscular route within 2 months of screening~* Have conditions contraindicating metformin and/or sulfonylurea use~* Have had a change in lipid-lowering agents within 6 weeks of screening~* Have received glucagon-like peptide-1 (GLP-1) analogs, or dipeptidyl peptidase-IV inhibitors (DPP-IV inhibitors) or have previously participated in this study~* Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): None
- Group B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Malaria Seasonal IPTc Combined With Community Case Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age between 3 to 120 months~* consent participation given by parents or guardians~* willing to remain in the study area in the next 6 months~Exclusion Criteria:~* Known allergy to the study investigational drug~* Any underlying chronic or severe condition.~* Participant under Treatment with sulfamides

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- Community Case Management (Type: PLACEBO_COMPARATOR): Provision of access to prompt diagnosis and treatment for malaria by community volunteers in the village (PECADOM)
- Community Case Management plus IPTc (Type: EXPERIMENTAL): Monthly Intermittent Preventive Treatment with sulfadoxine pyrimethamine plus amodiaquine, in addition to community case management

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Redesigned Process in the Operating Room

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients, above 18 years of age, undergoing general surgery for surgeon X under general anesthesia~* Patients undergoing only the following general surgeries: laparoscopic hernia, laparoscopic appendectomy, laparoscopic cholecystectomy, and laparoscopic gastric/band sleeve surgeries~* American Society of Anesthesiologist Physical Status (ASA) I or II~* Research participant willing to sign informed written consent.~Exclusion Criteria:~* Patients under 18 years of age~* Patients undergoing general surgery for surgeon X under regional or spinal anesthesia~* Patients undergoing surgeries other than the following: laparoscopic hernia, laparoscopic appendectomy, laparoscopic cholecystectomy, and laparoscopic gastric/band sleeve surgeries~* American Society of Anesthesiologist Physical Status (ASA) III, IV, V, and VI~* Emergency and lifesaving Cases~* Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.~* Inability to bring the next patient to the induction room for uncontrollable reasons such as failure of equipment, late arrival to the hospital, or late financial or medical clearance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Standard process (Type: PLACEBO_COMPARATOR): The control group is placebo group and this is our standard practice. Patients will be induced in the operating room and at the end of surgery will be reversed with neostigmine 50µg/kg and glycopyrrolate 10µg/kg. Once extubated and rolled out of the room, the house keeper team will start cleaning the operating room
- Redesigned process (Type: ACTIVE_COMPARATOR): Patients will be inducted in the induction room. At the end of surgery and after placement of the surgical dressing, the registered nurse will call in the house keeper to start cleaning of the OR (parallel processing) before the patient exits the room. The patient will be reversed with sugammadex 4mg/kg IV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Escitalopram in Depressive Patients With Acute Coronary Artery Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18\~85~* Diagnosed as acute CAS (unstable angina or acute myocardial infarction) and being conducted coronary angiography~* Beck Depression Inventory \> 10 and major or minor depressive disorder by the DSM-IV criteria~* With ability to complete various questionnaires~* Can understand the objective of the study and sign informed consent~Exclusion Criteria:~* Occurrence of acute CAS while the patient was hospitalized for another reason, except for CAS~* Current CAS developed less than 3 months after coronary artery bypass graft procedure~* Uncontrolled hypertension (systolic BP \> 180mmHg or diastolic BP \> 100mmHg)~* Resting heart rate \< 40/min~* Severe physical illnesses threatening life or interfering with the recovery from CAS~* Persistent clinically significant laboratory abnormalities~* Concomitant use of class I antiarrhythmic medications; reserpine, guanethidine, clonidine, or methyldopa; anticonvulsants or neuroleptics~* History of neuropsychiatric illnesses such as dementia, Parkinson's disease, brain tumor, psychoses, alcoholism, and other substance dependence~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Escitalopram (Type: EXPERIMENTAL): None
- Placebo pill (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete